产品名称
C18(2S-OH) Galactosyl(β) Ceramide, Avanti Research™ - A Croda Brand
assay
>99% (TLC)
SMILES string
[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC([C@@H](O)CCCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@H]([C@H]1CO)O
form
powder
packaging
pkg of 1 × 5 mg (860841P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
Biochem/physiol Actions
Galactosyl(β) Ceramide acts as a globotriaosylceramide synthase substrate to produce galabiaosylceramide. Altered levels of this lipid is associated with the development of various diseases including malignancy, sphingolipidosis, diabetes and chronic kidney diseases.
General description
C18(2S-OH) Galactosyl(β) Ceramide, also known as D-galactosyl-β1-1′-N-[2′′(S)-hydroxystearoyl]-D-erythro-sphingosine is a hexosylceramide. Galactosyl(β) Ceramide synthesis is catalyzed by the enzyme β-GalCer synthase (UGT8A).
Packaging
5 mL Amber Glass Screw Cap Vial (860841P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
No data available
flash_point_c
No data available
法规信息
涉药品监管产品
此项目有
Johanna von Gerichten et al.
Journal of lipid research, 58(6), 1247-1258 (2017-04-05)
Mammals synthesize, cell-type specifically, the diastereomeric hexosylceramides, β-galactosylceramide (GalCer) and β-glucosylceramide (GlcCer), which are involved in several diseases, such as sphingolipidosis, diabetes, chronic kidney diseases, or cancer. In contrast, Bacteroides fragilis, a member of the human gut microbiome, and the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持